In this study, the effect size identified for reduction in stroke risk (HR 0.74) is comparable to or exceeds that of meta-analyses investigating the effects of lowering blood pressure (RR 0.73), treating hyperlipidemia (RR 0.79), and other interventions in people with T2D [30], highlighting the benefits that can be achieved by adding GLP-1 RAs to antihyperglycemic regimens. The gene discussed is GLP1R; the disease is hyperlipidemia.